1234708-04-3
1234708-04-3
Chemical Structure
hPGDS-IN-1
- CAS No.: 1234708-04-3
- Formula:C22H20N6O3
- Molecular Weight:416.43
IUPAC Name: N-(3-(5-(2-hydroxypropan-2-yl)-1,2,4-oxadiazol-3-yl)benzyl)-2-(pyridin-2-yl)pyrimidine-5-carboxamide
InChIKey: VJCLAPUACUQZOV-UHFFFAOYSA-N
SMILES: OC(C)(C)C1=NC(C2=CC(CNC(C(C=N3)=CN=C3C4=CC=CC=N4)=O)=CC=C2)=NO1
Biological Activity: hPGDS-IN-1 (Compound 2[3]) is an hPGDS inhibitor with an IC50 of 12 nM (as measured by fluorescence polarization assay or EIA). hPGDS-IN-1 can be used in the research of allergic rhinitis and spinal cord neurons[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
hPGDS-IN-1 | 99.92% | hPGDS-IN-1 (Compound 2) is an hPGDS inhibitor with an IC50 of 12 nM (as measured by fluorescence polarization assay or EIA). hPGDS-IN-1 can be used in the research of allergic rhinitis and spinal cord neurons. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Vandeusen, Christopher L, et al. Phenyloxadiazole derivatives as PGD inhibitors and their preparation, pharmaceutical compositions and use in the treatment of allergic and inflammatory disorders. From PCT Int. Appl. (2011), WO 2011044307 A1 20110414.
- [2]. Hahn Chang S. Method for treating macular degeneration using syk multikinase inhibitor, an hPGDS inhibitor and a DP antagonist. From PCT Int. Appl. (2010), WO 2010080563 A2 20100715.
- [3]. Weiberth Franz J, et al. Demonstration on Pilot-Plant Scale of the Utility of 1,5,7-Triazabicyclo[4.4.0]dec-5-ene (TBD) as a Catalyst in the Efficient Amidation of an Unactivated Methyl Ester. From Organic Process Research & Development (2012), 16(12), 1967-1969.
